These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8993553)

  • 41. An overview of peroxisome proliferator-induced hepatocarcinogenesis.
    Rao MS; Reddy JK
    Environ Health Perspect; 1991 Jun; 93():205-9. PubMed ID: 1685443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diverse mechanisms of calcium mobilization by peroxisome proliferators in rat hepatocytes.
    Shackleton GL; Gibson GG; Sharma RK; Howes D; Orrenius S; Kass GE
    Toxicol Appl Pharmacol; 1995 Feb; 130(2):294-303. PubMed ID: 7871541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of hepatic ornithine decarboxylase by hypolipidemic drugs with hepatic peroxisome proliferative activity.
    Izumi K; Reddy JK; Oyasu R
    Carcinogenesis; 1981; 2(7):623-7. PubMed ID: 7273341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of peroxisome proliferators on protein abundances in mouse liver.
    Anderson NL; Esquer-Blasco R; Richardson F; Foxworthy P; Eacho P
    Toxicol Appl Pharmacol; 1996 Mar; 137(1):75-89. PubMed ID: 8607144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of the major integral membrane protein of mouse liver peroxisomes by peroxisome proliferators.
    Chen N; Crane DI
    Biochem J; 1992 Apr; 283 ( Pt 2)(Pt 2):605-10. PubMed ID: 1575703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-induction by peroxisome proliferators of microsomal 1-acylglycerophosphocholine acyltransferase with peroxisomal beta-oxidation in rat liver.
    Kawashima Y; Horii S; Matsunaga T; Hirose A; Adachi T; Kozuka H
    Biochim Biophys Acta; 1989 Sep; 1005(2):123-9. PubMed ID: 2570610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of peroxisome proliferation and liver growth-stimulating potential by nondirectly genotoxic compounds in cultured hepatocytes.
    Bieri F; Stäubli W; Kelly S; Waechter F; Bentley P
    Mol Toxicol; 1987-1988 Fall; 1(4):439-44. PubMed ID: 3151502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unusual responses of rat hepatic and renal peroxisomes to RMI 14, 514, a new hypolipidemic agent.
    Svoboda DJ
    J Cell Biol; 1978 Sep; 78(3):810-22. PubMed ID: 29903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
    Alegret M; Ferrando R; Vázquez M; Adzet T; Merlos M; Laguna JC
    Br J Pharmacol; 1994 Jun; 112(2):551-6. PubMed ID: 7915611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accelerated regression of carcinogen-induced preneoplastic hepatocyte foci by peroxisome proliferators, BR931, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio (N-B-hydroxyethyl)acetamide, and di-(2-ethylhexyl)phthalate.
    Perera MI; Shinozuka H
    Carcinogenesis; 1984 Sep; 5(9):1193-8. PubMed ID: 6147206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
    Cattley RC; DeLuca J; Elcombe C; Fenner-Crisp P; Lake BG; Marsman DS; Pastoor TA; Popp JA; Robinson DE; Schwetz B; Tugwood J; Wahli W
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):47-60. PubMed ID: 9629596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
    Prueksaritanont T; Qiu Y; Mu L; Michel K; Brunner J; Richards KM; Lin JH
    Pharm Res; 2005 Jul; 22(7):1101-9. PubMed ID: 16028010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatocarcinogenesis of peroxisome proliferators.
    Rao MS; Reddy JK
    Ann N Y Acad Sci; 1996 Dec; 804():573-87. PubMed ID: 8993574
    [No Abstract]   [Full Text] [Related]  

  • 54. Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect.
    Azarnoff DL; Svoboda DJ
    Arch Int Pharmacodyn Ther; 1969 Oct; 181(2):386-93. PubMed ID: 4397540
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
    Hung YJ; Pei D; Wu DA; Kuo SW; Fuh MM; Jeng C
    J Formos Med Assoc; 1999 Feb; 98(2):104-10. PubMed ID: 10083765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peroxisome proliferation and hepatotoxicity in rodents.
    Grasso P
    Biochem Soc Trans; 1985 Oct; 13(5):861-2. PubMed ID: 4065422
    [No Abstract]   [Full Text] [Related]  

  • 57. Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
    Clavey V; Copin C; Mariotte MC; Baugé E; Chinetti G; Fruchart J; Fruchart JC; Dallongeville J; Staels B
    Cell Physiol Biochem; 1999; 9(3):139-49. PubMed ID: 10494028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Partial purification and immunoreactivity of an 80 000-molecular-weight polypeptide associated with peroxisome proliferation in rat liver.
    Reddy MK; Hollenberg PF; Reddy JK
    Biochem J; 1980 Jun; 188(3):731-40. PubMed ID: 6781475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of bromodeoxyuridine labeling in hepatomegaly produced by peroxisomal proliferation or P-450 induction in rodents.
    Smith PF; O'Brien KA; Keenan KP
    Prog Clin Biol Res; 1991; 369():285-9. PubMed ID: 1946525
    [No Abstract]   [Full Text] [Related]  

  • 60. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.